Axis Direct Broker Research reports

We maintain our BUY rating on the stock.

Considering the near-term challenges, we have downgraded the stock from BUY to HOLD and revised our TP to Rs 355/share, implying an upside potential of 7% from the CMP.

We maintain our BUY rating on the stock.

We maintain our HOLD recommendation on the stock.

We maintain our BUY recommendation on the stock.

We downgrade our rating on the stock from HOLD to SELL owing to a slowdown in the momentum and risks posed by tariff-related uncertainties.

We maintain our BUY rating on the stock.

Asian Markets are trading positively, tracking Wall Street gains as US inflation data fuels hopes for a Fed rate cut. The Nikkei, Hang Seng and Shanghai are all trading positively by 1.37%, 1.02% and 0.36%, respectively.

We recommend a BUY rating (earlier HOLD) on the company.

We maintain our BUY rating on the stock.

We maintain our BUY recommendation on the stock

Asian Markets are mostly trading mixed as investors assess the US-China tariff truce extension overnight. The Nikkei and Shanghai are both trading positively, by 2.29% and 0.24%, respectively, whereas the Hang Seng is trading negatively by 0.16%.

We recommend a BUY on the stock with a TP of Rs 996 /share, implying a 10% upside from the CMP

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

We maintain a BUY rating on Medanta, supported by the expected recovery from temporary business disruptions, improvement in ARPOB, and incremental bed capacity addition, including the Noida hospital, which is likely to be operational by the end of H1FY26E.

We maintain our BUY recommendation on the stock.

We maintain our HOLD rating on the stock.

We maintain our BUY rating.

With a 32% upside from the CMP, we maintain our long-term BUY rating on the stock.

We maintain our BUY recommendation on reasonable valuations.